Pd0166285
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase. | Bioorganic & medicinal chemistry letters 20120115 |
| WEE1 inhibition sensitizes osteosarcoma to radiotherapy. | BMC cancer 20110101 |
| 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives. | Bioorganic & medicinal chemistry 20080115 |
| Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. | BMC cancer 20060101 |
| Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. | Bioorganic & medicinal chemistry letters 20050401 |
| Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. | Radiation research 20020301 |
| Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. | Cancer research 20011115 |
| 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. | Journal of medicinal chemistry 19980813 |
| Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. | Journal of medicinal chemistry 19980521 |
| In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. | The Journal of pharmacology and experimental therapeutics 19971201 |